ArticleBMC biology2025
NeXtMD: a new generation of machine learning and deep learning stacked hybrid framework for accurate identification of anti-inflammatory peptides.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Multi-Omics Integration Framework with Automated Machine Learning Identifies Peripheral Immune-Coagulation Biomarkers for Schizophrenia Risk Stratification.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAccurate identification of anti-inflammatory peptides (AIPs) is crucial for drug development and inflammatory disease treatment. However, the short length and limited informational content of peptide sequences make precise computational recognition particularly challenging. While various machine learning and deep learning approaches have been explored, their limitations in feature representation and model integration hinder the effective discovery of novel AIPs.
resultsIn this study, we present NeXtMD, a novel dual-module stacked framework that integrates both machine learning (ML) and deep learning (DL) components for accurate AIP identification. NeXtMD systematically extracts four functionally relevant sequence-derived descriptors-residue composition, inter-residue correlation, physicochemical properties, and sequence patterns-and utilizes a two-stage prediction strategy. The first stage generates preliminary predictions using four distinct encoding strategies and ML classifiers, while the second stage employs a multi-branch residual network (ResNeXt) to refine prediction outputs. Benchmark evaluations demonstrate that NeXtMD outperforms current state-of-the-art methods on multiple performance metrics. Moreover, NeXtMD maintains strong generalization capabilities when applied to unseen peptide sequences, showing its robustness and scalability.
conclusionsNeXtMD offers a high-performance and interpretable computational framework for AIP identification, with significant potential to facilitate the discovery and design of peptide-based anti-inflammatory therapeutics. The architecture and methodological innovations of NeXtMD also provide a generalizable strategy that can be adapted to other bioactive peptide prediction tasks, supporting broader applications in therapeutic peptide development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.